Design and evaluation of a novel peptide-EV complex for targeted Alzheimer's disease therapy.
H102-CP05 shows potential in inhibiting Aβ fibrillation, but further in vivo studies are needed to assess safety and efficacy.
Where it sits
this study against the rest of the tesofensine corpusSummary and findings
The study designed a chimeric peptide H102-CP05 for Alzheimer's disease therapy, integrating a β-sheet breaker and a CD63-targeting anchor for EV-mediated delivery. Computational and in vitro analyses assessed its physicochemical properties, immunogenicity, cytotoxicity, and Aβ fibrillation inhibition. Zebrafish studies evaluated developmental safety and cardiovascular effects.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that involves the formation of amyloid-β (Aβ) aggregates, and the development of targeted therapeutic strategies is needed. In the current work, we report the rational design of H102-CP05, a 22-residue chimeric peptide that integrates the β-sheet breaker peptide H102 with the CD63-targeting anchor CP05 to enable extracellular vesicle (EV)-mediated delivery of an Aβ-inhibitory payload. Computational analysis confirmed favorable physicochemical properties and a non-allergenic profile. In silico immunogenicity assessment and C-IMMSIM simulation demonstrated a low risk of anti-drug antibody formation under chronic dosing conditions. Homology modelling and HADDOCK docking (score: -147.2 ± 4.6) predicted a computationally favourable CD63 binding configuration, while 100 ns molecular dynamics simulations confirmed structural stability in both aqueous and EV-mimetic lipid bilayer environments. In vitro cytotoxicity against HEK-293 cells revealed no significant toxicity (10-100 µM). Zebrafish embryo studies indicated acceptable developmental safety at lower concentrations, with concentration-dependent bradycardia observed at higher doses warranting further cardiovascular evaluation. Thioflavin T fluorescence assays demonstrated dose-dependent inhibition of Aβ fibrillation, with near-complete suppression at 100 µM. These findings collectively support H102-CP05 as a promising EV-displayed therapeutic candidate for AD.
Background
Alzheimer's disease is characterized by amyloid-β (Aβ) aggregates, necessitating targeted therapeutic strategies. Previous approaches have explored various delivery mechanisms to inhibit Aβ aggregation. This study aims to develop a novel peptide-EV complex to enhance targeted delivery and efficacy in Alzheimer's therapy.
Methods
The study involved the design of a 22-residue chimeric peptide, H102-CP05, combining a β-sheet breaker and a CD63-targeting anchor. Computational analyses assessed physicochemical properties, immunogenicity, and binding configurations. In vitro cytotoxicity was tested on HEK-293 cells, and zebrafish embryo studies evaluated developmental safety. Thioflavin T assays measured Aβ fibrillation inhibition.
Results
HADDOCK docking predicted favorable CD63 binding with a score of -147.2 ± 4.6. In vitro tests showed no significant cytotoxicity in HEK-293 cells at 10-100 µM. Zebrafish studies indicated developmental safety at lower concentrations, but higher doses caused bradycardia. Thioflavin T assays demonstrated dose-dependent Aβ fibrillation inhibition, with near-complete suppression at 100 µM.
Interpretation
The study presents promising preclinical data for H102-CP05 as an Alzheimer's therapeutic, particularly in Aβ fibrillation inhibition. However, the reliance on computational and in vitro models limits the immediate clinical applicability. The observed bradycardia in zebrafish suggests potential cardiovascular risks that need further investigation.
Key findings
- HADDOCK docking score: -147.2 ± 4.6
- No significant cytotoxicity in HEK-293 cells at 10-100 µM
- Near-complete Aβ fibrillation suppression at 100 µM
- Concentration-dependent bradycardia in zebrafish embryos at higher doses
Limitations
- Computational and in vitro models only
- Zebrafish embryo study, not mammalian
- Potential cardiovascular effects observed
- No human data